The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Promising therapies for Richter’s transformation: ven-R-CHOP, epcoritamab, pirtobrutinib & CAR-T
Adam Kittai, MD, Ohio State University, Columbus, OH, outlines promising therapies currently under investigation for the treatment of Richter’s transformation in the first-line setting, including the combination of venetoclax and R-CHOP, pirtobrutinib, epcoritamab, and CAR-T therapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Consultancy; Astrazeneca: Consultancy, Research Funding; Beigene: Consultancy; Janssen: Consultancy.
